ABBOTT LABORATORIES (ABT) Stock Price, Forecast & Analysis

NYSE:ABT • US0028241000

111.47 USD
-2.12 (-1.87%)
At close: Feb 12, 2026
111.37 USD
-0.1 (-0.09%)
After Hours: 2/12/2026, 8:26:51 PM

ABT Key Statistics, Chart & Performance

Key Statistics
Market Cap193.83B
Revenue(TTM)44.33B
Net Income(TTM)13.98B
Shares1.74B
Float1.73B
52 Week High141.23
52 Week Low105.27
Yearly Dividend2.21
Dividend Yield2.31%
EPS(TTM)5.15
PE21.64
Fwd PE19.41
Earnings (Next)04-14
IPO1937-03-01
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
ABT short term performance overview.The bars show the price performance of ABT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10 -15

ABT long term performance overview.The bars show the price performance of ABT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 -10

The current stock price of ABT is 111.47 USD. In the past month the price decreased by -10.82%. In the past year, price decreased by -14.65%.

ABBOTT LABORATORIES / ABT Daily stock chart

ABT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
ABT Full Technical Analysis Report

ABT Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ABT. ABT has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ABT Full Fundamental Analysis Report

ABT Financial Highlights

Over the last trailing twelve months ABT reported a non-GAAP Earnings per Share(EPS) of 5.15. The EPS increased by 10.28% compared to the year before.


Industry RankSector Rank
PM (TTM) 31.88%
ROA 16.6%
ROE 27.43%
Debt/Equity 0.23
Chartmill High Growth Momentum
EPS Q2Q%11.94%
Sales Q2Q%4.42%
EPS 1Y (TTM)10.28%
Revenue 1Y (TTM)5.67%
ABT financials

ABT Forecast & Estimates

35 analysts have analysed ABT and the average price target is 136.02 USD. This implies a price increase of 22.03% is expected in the next year compared to the current price of 111.47.

For the next year, analysts expect an EPS growth of 11.5% and a revenue growth 7% for ABT


Analysts
Analysts79.43
Price Target136.02 (22.02%)
EPS Next Y11.5%
Revenue Next Year7%
ABT Analyst EstimatesABT Analyst Ratings

ABT Ownership

Ownership
Inst Owners81.33%
Ins Owners0.45%
Short Float %1.15%
Short Ratio2.28
ABT Ownership

ABT Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ISRG INTUITIVE SURGICAL INC46.82175.875B
SYK STRYKER CORP24.2139.086B
BSX BOSTON SCIENTIFIC CORP21.16108.957B
IDXX IDEXX LABORATORIES INC41.6651.801B
BDX BECTON DICKINSON AND CO11.2851.46B
EW EDWARDS LIFESCIENCES CORP25.7146.035B
RMD RESMED INC20.0137.897B
GEHC GE HEALTHCARE TECHNOLOGY15.6636.095B
DXCM DEXCOM INC25.7826.58B

About ABT

Company Profile

ABT logo image Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.

Company Info

ABBOTT LABORATORIES

100 Abbott Park Road, Abbot Park

ABBOTT PARK ILLINOIS 60064 US

CEO: Robert B. Ford

Employees: 114000

ABT Company Website

ABT Investor Relations

Phone: 12246676100

ABBOTT LABORATORIES / ABT FAQ

What does ABT do?

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.


What is the stock price of ABBOTT LABORATORIES today?

The current stock price of ABT is 111.47 USD. The price decreased by -1.87% in the last trading session.


Does ABT stock pay dividends?

ABBOTT LABORATORIES (ABT) has a dividend yield of 2.31%. The yearly dividend amount is currently 2.21.


What is the ChartMill rating of ABBOTT LABORATORIES stock?

ABT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is ABBOTT LABORATORIES (ABT) stock traded?

ABT stock is listed on the New York Stock Exchange exchange.


How is the market expecting ABT stock to perform?

35 analysts have analysed ABT and the average price target is 136.02 USD. This implies a price increase of 22.03% is expected in the next year compared to the current price of 111.47.


Should I buy ABT stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ABT.